- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 25
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 25, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 25.
Number 5: With the Graham-Cassidy bill dead in the Senate, efforts at healthcare reform have turned to the issue of the high cost of prescription drugs.
Number 4: The European Medicines Agency has warned that it could lose 94% of its staff when it is forced to relocate from its current home in London as the United Kingdom finalizes its withdrawal from the European Union.
Number 3: Celltrion and Teva’s rituximab biosimilar CT-P10, currently under review by the FDA, shows comparable safety and efficacy to its reference, Rituxan, in a new network meta-analysis.
Number 2: Amgen has filed a new Biologics Price Competition and Innovation Act lawsuit against rival drug maker, Mylan. Amgen asserts that Mylan infringed on 2 patents covering Neulasta when it developed its pegfilgrastim biosimilar.
Number 1: AbbVie, maker of Humira, has reached a settlement with Amgen concerning its adalimumab biosimilar, Amgevita. The agreement clears the way for the biosimilar to launch in the European Union in 2018, and in the United States in 2023.
Finally, last week, our newsletter for your input on what factors will determine clinical uptake of the newly approved bevacizumab biosimilar. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
